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ABSTRACT 
Nifedipine has been formulated and marketed as extended-release-film coated tablet. A certain degree of success has been achieved 
in reducing the incidence of adverse effects by the use of slow-release formulations such as nifedipine retard. The aim of the present 
study was to evaluate the physicochemical quality attributes and in vitro equivalence of six brands of nifedipine retard tablets 
available in different retail outlets in Addis Ababa, Ethiopia. After constructing the calibration curve, the in vitro drug release studies 
were carried out using USP type I dissolution apparatus at 100 rpm. The dissolution was done in a medium of 0.1N HCl containing 
0.5% sodium lauryl sulfate for 12 hrs. All the tablets met the requirement for tablet weight uniformity. The mean crushing strengths 
of sample tablets ranged from 49.2 to 111.2 N. All the brands studied released more than 80% within 12 hours which is within the 
tolerance limit.  However, the release profile revealed that five of the brands showed over 15% drug release at 1st hour except 
product F which released only 14.32%. In conclusion, all the brands of tablets had uniform thickness and good hardness. Despite all 
the brands had sustained the release for over 12 hours recommended for such formulations, five of them showed higher release in the 
first hour which may affect their in vivo performance. 
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INTRODUCTION 
Hypertension is a major public health problem world-
wide with its attendant high rate of morbidity and 
mortality. Hypertension is a progressive disease that 
affects more than 1 billion people worldwide
1,2
.
 
 Reports 
showed that an estimated 639 million individuals had 
hypertension in developing countries in 2000 and this 
number is expected to rise to 1.15 billion by 2025
3
.  
The primary goal of antihypertensive therapy is to 
control blood pressure and reduce the long-term risk of 
cardiovascular morbidity and mortality.  Different 
classes of medication are available for the management 
of hypertension
4,5,6
. Nifedipine [Dimethyl-2,6-methyl-4-
( 2-nitrophenyl)-1, 4-dihydropyridine-3, 5-
dicarboxylate]  (Fig 1) is a calcium channel blocking 
agent which is commonly employed in the management 
of systemic hypertension and angina pectoris
7
. 
 
Figure 1: Chemical structure of nifedipine
7
 
It has been demonstrated that the use of immediate-
release nifedipine oral formulations have been 
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associated with rapid increase in nifedipine plasma 
concentration which results in increased heart rate and 
drug speciﬁc side effects such  as  flushing,  dizziness,  
palpitation  and reflex  tachycardia. Accordingly, it is 
generally accepted that modiﬁed release formulations of 
nifedipine are the ﬁrst therapeutic choice1,4,6.8,9.  
Sustained release nifedipine is prepared as an extended-
release-film coated tablet. A certain degree of success 
has been achieved in reducing the incidence of such 
adverse effects by the use of slow-release formulations 
such as nifedipine retard
10,11,12
.
 
 
Expiration of drug patents lead to several companies 
producing generic forms of drugs
13
. However, quality 
and performance of the generic versions of such drugs 
used in the management of chronic complications have 
been a source of debate among professionals and 
patients, particularly in the light of increasing circulation 
of counterfeited products and absence of strong 
regulatory systems in developing countries. The 
marketing of multisource drug products registered by 
national drug agencies in developing countries, with the 
view of improving health care delivery through 
competitive pricing, has an attendant problem of 
ascertaining their quality and interchangeability. As a 
result, health-care professionals sometimes pose 
questions whether these generics are equivalent to their 
original counterparts and whether patients are put at 
risk
14,15
.  
The formulation of a tablet drug product can have a 
significant effect on its physicochemical quality 
parameters such as hardness, weight variation, 
disintegration time, dissolution profile which may in 
turn affect the in vivo performance. Hence, the present 
study was carried out to evaluate the physicochemical 
quality and in vitro equivalence of six brands of 
nifedipine retard tablets marketed by different retail 
outlets in Addis Ababa, Ethiopia. 
MATERIALS AND METHODS 
Materials 
Six different brands of 20 mg nifedipine retard tablets 
(Table 1) were purchased from retail outlets in Addis 
Ababa. All were film coated tablets except product C. 
Nifedipine reference standard was kindly donated by the 
Ethiopian Food, Medicine and Healthcare 
Administration and Control Authority (EFMHACA).  
Hydrochloric acid (BDH limited, Poole, England), 
HPLC grade methanol (Park Scientific Limited, UK), 
sodium lauryl sulfate, distilled water were used for the 
study.  All chemicals used were analytical grade.  
  
Table 1: Detailed description of products of nifedipine 20mg retard tablets included in the study 
Brand Code Manufacturer Country of origin Batch no Expiry date 
A Cipla India GD61923 05/2019 
B Fabricadop Germany 19021 08/2019 
C Cadila India G603016 06/2019 
D Remedica Cyprus 69778 09/2019 
E E.I.P.I.Co Egypt 1509228 10/2018 
F Cadila India D50025350 09/2017 
 
Methods 
Measurement of thickness 
Ten tablets from each brand were taken and thickness 
was measured using sliding caliper scale (Nippon 
Sokutei, Japan). Results were expressed as a mean and 
standard deviation. 
Crushing strength   
Ten tablets were randomly selected from each brand 
product and the crushing strengths of the tablets were 
determined using hardness tester (Schleuniger, 2E/205, 
Switzerland). Each tablet was placed between two anvils 
and force was applied to the anvils, and the crushing 
strength that just caused the tablet to break was 
recorded. Results were expressed as a mean and 
standard deviation.  
Weight variation 
The weight variation test was evaluated by taking 
twenty tablets from each of the six brands, weighed 
individually with an analytical balance. The average 
weights for each brand as well as the percentage 
deviation from the mean value were calculated. Weight 
variation results were demonstrated as per USP (2013). 
Disintegration time 
Disintegration time test was carried out according to 
USP/NF (2013) specification. Six tablets were placed in 
a disintegration tester (CALEVA, G.B. Caleva Ltd., 
UK) filled with distilled water at 37±0.5°C. The tablets 
were considered completely disintegrated when all the 
particles are passed through the wire mesh and time was 
recorded.
 
Calibration curve for Nifedipine RS  
Various concentrations of Nifedipine RS (17.5, 20, 25, 
30, 35, 40, 45 and 50 µg/ml) were prepared in a medium 
of 0.1N HCl containing 0.5% sodium lauryl sulfate and 
methanol. Absorbances were measured at max of 329 
nm using a UV-Visible spectrophotometer (SOLAR 
Spectrofluorimeter, CM2203, Belarus). The values of 
absorbance were plotted against the corresponding 
concentrations.  
In vitro drug release studies  
The in vitro drug release studies were carried out using 
USP type I dissolution apparatus (ERWEKA, DT600, 
Germany) at 100 rpm. The dissolution was done in a 
medium of 900 ml 0.1N HCl containing 0.5% sodium 
lauryl sulphate for 12 hrs.  The temperature was 
Agune et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2018; 8(3):1-5                
ISSN: 2250-1177                                                                                 [3]                                                                              CODEN (USA): JDDTAO 
maintained at 37±0.5 °C. Aliquot samples  of  10 ml  
were  withdrawn  at  pre  scheduled  intervals (1, 3, 4, 6, 
and 12 h) and  replaced  with  an equal volume of fresh 
dissolution  medium  which was kept at 37±0.5 °C  to  
maintain  sink  condition. Each filtered sample was 
analyzed for drug content at max of 329 nm using a 
UV/Visible Spectrophotometer.  
Statistical analysis 
Origin 7 Software (OriginLab Corporation, MA, and 
USA) was used to statistically analyze the results. All 
the data measured and reported are averages of a 
minimum of triplicate measurements and the values are 
expressed as mean ± standard deviation. 
RESULTS AND DISCUSSION 
Tables  2  and  3  show  some  of  the  physicochemical 
characteristics  of  the  nifedipine retard tablets  studied. 
All tablets met the requirement (USP, 2013) for tablet 
weight uniformity and no tablet deviated from the 
average weight by more than 10% (samples A, C, D, E 
and F) and 7.5% (sample B). This compliance is 
important  since  the  uniformity of  dosage  unit  can be 
demonstrated by either  weight  variation  or  content 
uniformity  study  (USP/NF,  2013).  
  
Table 2: Tablet weights of the nifedipine 20 mg retard samples used in the study 
Tablet 
No 
Weight (mg) 
A B C D E F 
1 83.0 181.7 94.4 87.1 93.0 112.8 
2 83.1 176.4 95.0 86.0 92.3 110.4 
3 83.0 173.8 95.4 87.5 94.2 111.8 
4 81.6 170.0 94.6 88.3 93.5 110.6 
5 83.6 175.8 96.0 87.8 93.5 110.3 
6 84.7 176.0 95.8 87.7 95.3 111.9 
7 84.4 174.2 94.6 87.2 96.2 111.4 
8 82.2 175.3 95.2 86.0 94.4 110.8 
9 85.5 177.3 96.2 88.4 94.3 112.6 
10 84.7 174.5 94.4 87.7 94.9 112.8 
11 84.7 172.9 96.2 87.8 95.9 112.9 
12 82.2 179.3 95.8 90.0 94.7 109.9 
13 84.3 170.8 97.3 87.6 94.2 116.0 
14 84.0 175.3 94.7 86.9 88.0 110.6 
15 83.5 175.2 94.3 86.7 91.5 111.7 
16 82.7 177.5 94.4 87.9 97.3 113.2 
17 83.6 177.1 94.1 87.6 91.1 107.6 
18 82.4 177.0 96.6 88.5 94.6 111.8 
19 82.2 174.5 94.5 87.6 93.7 110.3 
20 84.7 181.0 95.1 88.3 93.3 111.4 
 
The tablet thickness ranged from 2.69 (product D and E) 
to 3.43 mm (product F). The mean crushing strengths of 
sample tablets ranged from 49.2 to 111.2 N. Sufficient 
tablet hardness is essential to ensure resistance to 
damage by handling, packaging and transportation. 
Tablet hardness of 4 kg is considered to be the minimum 
for a satisfactory tablet
12
; hence all tablets conformed to 
the necessary requirements. Maximum and minimum 
crushing strengths were observed from product D and A, 
respectively. Such differences in crushing strength may 
be resulted from different formulation and 
manufacturing technology. 
 
Table 3: Some physicochemical characteristics of the nifedipine 20 mg retard samples studied 
Brand Tablet weight 
(mg) 
Thickness 
(mm) 
Crushing 
strength (N) 
Disintegration 
time  
A 83.51± 1.09 2.98 ± 0.02 49.2 ± 1.75 5min 10sec 
B 175.78± 2.91 3.26 ± 0.06 84.5 ±2.72 45 sec 
C 95.23 ±0.89 2.88 ± 0.05 72.7 ± 4.16 56 sec 
D 87.63 ± 0.89 2.69 ± 0.02 111.2 ± 4.24 1min 50 sec 
E 93.80 ± 2.02 2.69 ± 0.05 107.7 ± 4.62 3 hr 54 min 
F 111.54 ± 1.69 3.43 ± 0.04 92.4 ± 3.20 > 5 hr 
 
The disintegration time of the sample tablets showed 
great variation. Product B showed rapid disintegration 
time with only 45 seconds while with product F which 
remained intact even after 5 hrs. Such lowest 
disintegration time of product F may suggest slower 
dissolution rate.  
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Construction of Calibration Curve 
The absorbance reading of nifedipine reference standard 
obtained was plotted against concentration (Figure 2). 
The linear regression equations obtained was Y = 
0.01331X - 0.01291 (R
2
 = 0.9992) in 0.1 N HCl 
containing 0.5% sodium lauryl sulfate and methanol 
where Y is absorbance and X is concentration in µg/ml.     
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Figure 2: Standard calibration curve of nifedipine at max 
of 329 nm in 0.1N HCl containing 0.5% sodium lauryl 
sulfate and methanol with upper and lower 95% 
confidence limits. 
 
In vitro drug release 
Bioequivalence studies are important to predict 
therapeutic equivalence between pharmaceutical 
equivalent test and reference products. In vitro 
dissolution studies have been recognized as important 
predictors of bioavailability for products on which 
formulation variables and processing parameters could 
have significant influence
16,17
.  
Of the tests that can be performed on tablets, the 
dissolution test is considered to be sensitive, reliable and 
rational for predicting in-vivo drug availability 
behavior
18
. 
The drug release characteristics of dosage forms are 
usually tested by means of pharmacopoeial test methods 
under highly standardized conditions. These very well 
established methods are widely used as a tool for quality 
control and for the optimization of dosage forms
9
.  
The result of drug release profile from the six brands of 
nifedipine retard tablets is illustrated in Figure 3. 
According to USP (2013), the acceptance limit for the 
amount of nifedipine released is given in Table 4. All 
the brands of nifedipine retard tablets studied released 
more than 80% within 12 hours which is within the 
tolerance limit.  The release profile also revealed that 
five of brands showed more than 15% drug release at 1
st
 
hour while product F released 14.32% within the 1
st
 
hour. These results suggested that five of the studied 
brands (except F) exhibited higher initial drug release 
which may lead to dose dumping and compromise their 
therapeutic performance. Regarding the cumulative drug 
release within 4 hours, product F complied with USP 
dissolution tolerance limits (39%) but all others showed 
more release (>50%) than the stated amount within this 
period. Among all brands, product F had the least 
percentage release in the first 4 hours indicating its 
better retardant capacity than others.    
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Figure 3: In vitro release profiles of nifedipine 20 mg 
retard tablets 
Table 4: The cumulative percentage released of the 
labeled amount of nifedipine retard tablets at specified 
time (USP 2013). 
Time (hr) Amount released (%) 
1 Not more than 15% 
4 20%-40% 
12 Not less than 80% 
 
CONCLUSION  
In the present study, 6 different brands of nifedipine 20 
mg retard release tablets marketed in Addis Ababa were 
evaluated for different physicochemical properties. All 
the brands were found to have uniform thickness and 
weight and acceptable hardness.  The results obtained 
were satisfactory and within the specified limits.   
The first four brands were disintegrated within 15 
minutes while product E and product F failed to 
disintegrate before 3 and 5 hours, respectively. 
Based on the in-vitro dissolution studies, it was found 
that all brand products released more than 80% of the 
labeled amount within 12 hours in compliance with the 
USP tolerance limit. However, all brands except F 
released over 15% out of the acceptable monograph 
limit which may affect their in vivo performance. 
Similar pattern was observed up to 4 hrs where five of 
the brands released over 50% above the USP 
recommended tolerance limit and only product F could 
meet the requirement. 
Therefore, the results of the present study revealed that 
all the studied brands meet monogram specification for 
most of the physicochemical quality parameters but 
most of them (except F) failed to meet the 1
st
 and 4
th
 hr 
USP in vitro dissolution tolerance limits which may 
affect the in vivo performance of these drugs. 
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